Drug Search Results
More Filters [+]

KI-67

Alternative Names: ki-67, ki67, ki 67
Latest Update: 2024-10-29
Latest Update Note: News Article

Product Description

Ki-67 may be considered as a valuable biomarker in breast cancer patients.

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KI-67

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Non-Small-Cell Lung Cancer

Phase 2: Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NeoTAILOR

P2

Recruiting

Breast Cancer

2027-11-30

STUDY00006091

N/A

Not yet recruiting

Squamous Cell Carcinoma

2027-10-01

I-share

N/A

Recruiting

Uterine Cancer|Cervical Cancer

2027-02-01

ChiCTR2400079698

N/A

Not yet recruiting

Breast Cancer

2026-12-31

Recent News Events